National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK.
Nat Rev Drug Discov. 2013 Jul;12(7):543-59. doi: 10.1038/nrd4025.
Chronic obstructive pulmonary disease (COPD) is associated with chronic inflammation of the peripheral airways and lung parenchyma, which leads to progressive obstruction of the airways. Current management with long-acting bronchodilators does not reduce disease progression, and there are no treatments that effectively suppress chronic inflammation in COPD. An increased understanding of the inflammatory processes that are involved in the pathophysiology of COPD has identified several new therapeutic targets. This Review discusses some of the most promising of these targets, including new antioxidants, kinase inhibitors and drugs that target cellular senescence, microbial colonization, epigenetic regulation of inflammatory gene expression and corticosteroid resistance.
慢性阻塞性肺疾病(COPD)与外周气道和肺实质的慢性炎症有关,这导致气道进行性阻塞。目前采用长效支气管扩张剂进行治疗并不能减缓疾病进展,也没有能够有效抑制 COPD 慢性炎症的治疗方法。对参与 COPD 病理生理学的炎症过程的深入了解确定了几个新的治疗靶点。本综述讨论了其中一些最有希望的靶点,包括新型抗氧化剂、激酶抑制剂以及针对细胞衰老、微生物定植、炎症基因表达的表观遗传调控和皮质激素抵抗的药物。